High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

European Journal of Haematology

Volumn 85, Issue 2, 2010, Pages 114-119

  Terpos, Evangelos ^a   Katodritou, Eirini ^b   Roussou, Maria ^a   Pouli, Anastasia ^c   Michalis, Eurydiki ^d   Delimpasi, Sosana ^e   Parcharidou, Agapi ^f   Kartasis, Zafiris ^g   Zomas, Athanasios ^a   Symeonidis, Argiris ^h   Viniou, Nora Athina ^a   Anagnostopoulos, Nikolaos ^d   Economopoulos, Theofanis ^a   Zervas, Konstantinos ^b   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e EVANGELISMOS HOSPITAL   (Greece)

^f RED CROSS HOSPITAL   (Greece)

^g General Hospital of Chalkis   (Greece)

^h UNIVERSITY OF PATRAS   (Greece)

Author keywords

lactate dehydrogenase; multiple myeloma; novel agents; survival

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; PARAPROTEIN; THALIDOMIDE;

ADVANCED CANCER; AGE DISTRIBUTION; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCALCEMIA; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC AGENTS; FEMALE; GREECE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; PLATELET COUNT; PROGNOSIS; SURVIVAL RATE;

EID: 77954696788     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01466.x     Document Type: Article

References (15)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 111 : 2516 2520.
2. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009 23 : 1152 1157.
3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005 23 : 3412 3420.
4. Shaughnessy J Jr., Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003 120 : 44 52.
5. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008 22 : 1933 1937.
6. Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009 27 : 4197 4203.
7. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009 27 : 4585 4590.
8. Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009 94 : 372 379.
9. Simonsson B, Brenning G, Källander C, Ahre A. Prognostic value of serum lactic dehydrogenase (s-LDH) in multiple myeloma. Eur J Clin Invest 1987 17 : 336 339.
10. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 1989 110 : 521 525.
11. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991 115 : 931 935.
12. Suguro M, Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. Am J Hematol 2000 65 : 132 135.
13. Anagnostopoulos A, Gika D, Symeonidis A, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 2005 75 : 370 375.
14. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009 23 : 3 9.
15. Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie B. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol 2009 27 : 3510 3517.